Automate Your Wheel Strategy on RVTY
With Tiblio's Option Bot, you can configure your own wheel strategy including RVTY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol RVTY
- Rev/Share 23.8958
- Book/Share 62.6483
- PB 1.5362
- Debt/Equity 0.4568
- CurrentRatio 1.7533
- ROIC 0.0293
- MktCap 11416218044.0
- FreeCF/Share 4.2254
- PFCF 22.9481
- PE 47.5392
- Debt/Assets 0.2775
- DivYield 0.0029
- ROE 0.0315
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 4
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | RVTY | BofA Securities | Buy | Neutral | -- | $110 | Dec. 15, 2025 |
| Initiation | RVTY | Goldman | -- | Neutral | -- | $105 | Dec. 9, 2025 |
| Initiation | RVTY | Guggenheim | -- | Neutral | -- | -- | Oct. 16, 2025 |
| Upgrade | RVTY | UBS | Neutral | Buy | -- | $115 | May 1, 2025 |
| Downgrade | RVTY | Bernstein | Outperform | Market Perform | -- | $130 | Jan. 10, 2025 |
| Upgrade | RVTY | BofA Securities | Neutral | Buy | -- | $138 | Dec. 13, 2024 |
| Upgrade | RVTY | Barclays | Equal Weight | Overweight | $125 | $140 | Oct. 15, 2024 |
| Initiation | RVTY | Wells Fargo | -- | Equal Weight | -- | $130 | Aug. 28, 2024 |
News
Segmental Performance to Drive RVTY's Q1 Earnings: Is a Beat Likely?
RVTY
Published: April 25, 2025 by: Zacks Investment Research
Sentiment: Neutral
Published: April 25, 2025 by: Zacks Investment Research
Sentiment: Neutral
RVTY's first-quarter results are likely to reflect decent performance in the Diagnostics segment. The Life Sciences segment is likely to have faced continued challenges in China.
Read More
Revvity Stock Tumbles Despite Expanding Genomics England Alliance
RVTY
Published: March 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Published: March 21, 2025 by: Zacks Investment Research
Sentiment: Positive
RVTY expands its alliance with Genomics England to boost newborn genomic sequencing research, aiming to enhance early diagnosis and healthcare outcomes.
Read More
About Revvity, Inc. (RVTY)
- IPO Date 1965-07-06
- Website https://www.perkinelmer.com
- Industry Medical - Diagnostics & Research
- CEO Prahlad R. Singh
- Employees 11000
Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.